RCAG
CYTK icon

Rehmann Capital Advisory Group’s Cytokinetics CYTK Stock Holding History

Rehmann Capital Advisory Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$637 Buy
+56
New +$703 ﹤0.01% 1611

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Rehmann Capital Advisory Group's CYTK Position: Q3 2019 in Review

Rehmann Capital Advisory Group opened a new position in Cytokinetics (CYTK) in Q3 2019: 56 shares worth $637. The stake represents ﹤0.01% of the portfolio and ranks #1611 among its holdings.

148 funds tracked by Wall St. Rank hold CYTK as of Q3 2019.

  • Rehmann Capital Advisory Group held 56 shares of Cytokinetics worth $637 as of Q3 2019.
  • Cytokinetics was a new Rehmann Capital Advisory Group position in Q3 2019.
  • Cytokinetics made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1611 holding.
  • 148 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.